SPAC977.17 Antibody

What is SPAC977.17 and why is it significant for research?

SPAC977.17 (Uniprot ID: Q9P7T9) is a protein-coding gene found in Schizosaccharomyces pombe, commonly known as fission yeast. This organism serves as an important model system in molecular and cellular biology due to its relatively simple genomic structure and similarity to human cells in key cellular processes. The protein encoded by SPAC977.17 is significant for research because it provides insights into fundamental cellular mechanisms that are conserved across eukaryotes. Researchers utilize antibodies against this protein to study its expression patterns, localization, and functional roles in various cellular contexts. Understanding SPAC977.17's function contributes to broader knowledge about eukaryotic cell biology, potentially revealing insights that can be translated to more complex organisms including humans. The antibody against this protein allows for specific detection in various experimental settings, making it a valuable tool for researchers focusing on yeast biology and comparative genomics .

What are the validated applications for SPAC977.17 antibody?

Based on structural similarities with other well-characterized antibodies, SPAC977.17 antibody has been validated for several research applications. Western blotting represents the primary application, allowing researchers to detect the target protein in cell lysates and tissue samples with high specificity. Immunohistochemistry (IHC) and immunocytochemistry (ICC) protocols have also been optimized for this antibody, enabling localization studies of the target protein within cellular compartments. Immunoprecipitation (IP) can be performed to isolate the target protein and its binding partners for subsequent analysis. Additionally, the antibody may be suitable for ELISA-based quantification and flow cytometry applications, though these require careful optimization based on specific experimental conditions. Researchers should note that validation data is typically provided with the antibody and should be consulted for specific application parameters and expected results .

How should SPAC977.17 antibody be stored and handled to maintain activity?

Proper storage and handling of SPAC977.17 antibody is crucial for maintaining its activity and specificity. Based on standard protocols for similar antibodies, it is recommended to store the antibody at -20°C in small aliquots to minimize freeze-thaw cycles, which can cause protein denaturation and loss of activity. The antibody is typically supplied in a buffer containing PBS (pH 7.3), 1% BSA, 50% glycerol, and 0.02% sodium azide to maintain stability during long-term storage. When working with the antibody, always keep it on ice and avoid prolonged exposure to room temperature. Prior to use, centrifuge the antibody vial briefly to collect the solution at the bottom of the tube. For dilution, use buffers appropriate for the intended application, maintaining protein concentration with BSA or non-fat dry milk to prevent non-specific adsorption to tubes or plates. Record the date of first use and track the number of freeze-thaw cycles to monitor potential degradation over time. Most antibodies remain stable for at least one year when stored properly, but activity should be verified periodically using positive controls .

How should I design experiments to verify SPAC977.17 antibody specificity in my S. pombe strain?

Verifying antibody specificity is a critical step when working with SPAC977.17 antibody, particularly if you're using a strain that differs from the standard 972/ATCC 24843. Begin with a comprehensive Western blot analysis comparing wild-type yeast with a SPAC977.17 knockout strain, which serves as a negative control to confirm the absence of bands at the expected molecular weight (approximately based on protein sequence prediction). Include a positive control sample from cells where SPAC977.17 is known to be highly expressed or overexpressed through genetic manipulation. It's advisable to perform peptide competition assays where the antibody is pre-incubated with the immunizing peptide before probing your samples; this should eliminate specific binding if the antibody is truly specific. Additionally, cross-reactivity testing against related yeast proteins, particularly those with high sequence homology, will strengthen your specificity validation. Immunofluorescence microscopy comparing staining patterns between wild-type and knockout strains provides further confirmation of specificity while also revealing subcellular localization information. Document these validation experiments thoroughly, as they establish the foundation for all subsequent experimental interpretations and address a key concern in rigorous antibody-based research .

What are the optimal conditions for using SPAC977.17 antibody in Western blot applications?

For optimal Western blot detection of SPAC977.17 protein, begin with sample preparation by lysing S. pombe cells in a buffer containing appropriate protease inhibitors to prevent degradation of the target protein. Based on similar antibody protocols, a starting dilution of 1:2000 is recommended for Western blot applications, though this may require optimization based on your specific experimental conditions and protein expression levels. Use 5-10 μg of total protein per lane on a 10-12% SDS-PAGE gel to ensure adequate separation in the expected molecular weight range. Following transfer to a PVDF or nitrocellulose membrane, block with 5% non-fat dry milk or BSA in TBST for 1 hour at room temperature. Incubate with diluted SPAC977.17 antibody overnight at 4°C with gentle agitation to maximize specific binding while minimizing background. After washing with TBST (4-5 times, 5 minutes each), incubate with an appropriate HRP-conjugated secondary antibody (anti-mouse IgG for monoclonal antibodies) at 1:5000 dilution for 1 hour at room temperature. After final washes, develop using enhanced chemiluminescence (ECL) reagents and optimize exposure times based on signal strength. Include positive control samples from wild-type S. pombe and consider using a loading control antibody (e.g., anti-actin) to normalize protein loading across samples .

How can I integrate SPAC977.17 antibody into multi-parameter imaging experiments?

Integrating SPAC977.17 antibody into multi-parameter imaging experiments requires careful consideration of antibody compatibility, fluorophore selection, and protocol optimization. First, determine the subcellular localization of your target protein to select appropriate co-staining markers for organelles or structures of interest. When designing a multi-color immunofluorescence experiment, choose primary antibodies from different host species (e.g., mouse anti-SPAC977.17 paired with rabbit anti-organelle markers) to avoid cross-reactivity between secondary antibodies. Select fluorophores with minimal spectral overlap to reduce bleed-through artifacts; typical combinations might include Alexa Fluor 488 for SPAC977.17 detection alongside Alexa Fluor 568 and Alexa Fluor 647 for additional markers. Establish the optimal fixation method for preserving both your target protein and co-staining markers, as some epitopes are sensitive to particular fixatives (typically, 4% paraformaldehyde works well for most yeast proteins). Implement sequential staining protocols if antibody cross-reactivity is a concern, completing one staining sequence with appropriate blocking steps before beginning the next. Include appropriate controls including single-color controls for spectral compensation and secondary-only controls to assess background fluorescence. For quantitative analysis, standardize image acquisition settings across all samples and use software tools to correct for chromatic aberration prior to colocalization analysis .

What are the key considerations when using SPAC977.17 antibody for quantitative analysis?

Quantitative analysis using SPAC977.17 antibody requires strict adherence to standardized protocols to ensure reliability and reproducibility of results. Begin by establishing a standard curve with recombinant SPAC977.17 protein at known concentrations to determine the linear detection range of your assay system. For Western blot quantification, use internal loading controls (such as housekeeping proteins) that do not vary under your experimental conditions, and ensure that your signal intensity falls within the linear range of detection to avoid saturation effects that compromise quantification. When performing immunofluorescence quantification, maintain consistent exposure settings across all samples and include fluorescence intensity standards for normalization between experiments. It's crucial to include biological replicates (typically n≥3) and technical replicates to account for variability, and apply appropriate statistical analyses based on your experimental design. Be aware of potential confounding factors such as cell cycle stage, which may influence SPAC977.17 expression levels naturally in S. pombe. For ELISA-based quantification, carefully optimize antibody concentrations through checkerboard titration to achieve maximum sensitivity while maintaining specificity. Document all procedural details, including antibody lot numbers, as variations between lots can significantly impact quantitative results. Finally, validate your quantitative findings using an orthogonal method such as qPCR for mRNA levels or mass spectrometry for protein levels .

How can epitope mapping enhance SPAC977.17 antibody applications?

Epitope mapping provides crucial insights that can significantly enhance the utility of SPAC977.17 antibody in various research applications. Understanding the specific amino acid sequence recognized by the antibody enables researchers to predict potential cross-reactivity with homologous proteins and assess antibody compatibility with different experimental conditions. Through ELISA-based epitope mapping using recombinant protein fragments or synthetic peptide arrays, researchers can identify the precise binding region of the antibody, similar to the approach described for SARS-CoV-2 antibodies. This information is particularly valuable when working with protein variants, post-translationally modified proteins, or protein complexes where epitope accessibility may be compromised. Knowledge of the epitope location also informs experimental design decisions regarding protein denaturation conditions—if the epitope is conformational, native conditions may be required for antibody recognition. For antibodies with mapped epitopes, researchers can design blocking peptides for specificity controls or competition assays. Additionally, epitope information enables strategic pairing with other antibodies for sandwich assays or co-immunoprecipitation studies, ensuring that multiple antibodies can simultaneously bind without steric hindrance. As demonstrated with other antibodies, epitope mapping can help explain unexpected experimental results and guide troubleshooting when standard protocols fail to yield expected outcomes .

What strategies are effective for troubleshooting weak or non-specific signals?

When encountering weak or non-specific signals with SPAC977.17 antibody, a systematic troubleshooting approach is necessary to identify and resolve the underlying issues. For weak signals, first verify protein expression levels in your samples, as the target protein may be expressed at low levels under certain conditions. Try increasing the protein load (up to 20-30 μg per lane for Western blots) or decreasing antibody dilution (e.g., from 1:2000 to 1:1000) while monitoring background levels. Extending primary antibody incubation time (overnight at 4°C) and optimizing detection systems (consider more sensitive substrates like femto-ECL) can enhance signal detection. For non-specific signals, increase blocking stringency by using 5% BSA instead of milk or adding 0.1-0.3% Tween-20 to reduce hydrophobic interactions. Optimize washing steps by increasing wash duration and number of washes (5-6 washes of 10 minutes each). Consider using alternative blocking agents such as fish gelatin if conventional blockers prove ineffective. If background persists, try titrating the secondary antibody to lower concentrations or pre-absorbing it with yeast lysate lacking the target protein. For both issues, sample preparation is critical—ensure complete protein denaturation for Western blots and optimize fixation conditions for immunofluorescence to preserve epitope accessibility. Comparing multiple lots of the antibody can help identify lot-specific issues, and consulting published literature on related S. pombe proteins may provide insight into common technical challenges .

How does SPAC977.17 antibody compare to other S. pombe protein antibodies in terms of specificity and sensitivity?

When evaluating SPAC977.17 antibody against other S. pombe protein antibodies, several performance metrics must be considered for comprehensive comparison. The equilibrium dissociation constant (KD), which measures binding affinity, provides quantitative data for comparison—high-quality antibodies typically exhibit KD values in the range of 10^-9 to 10^-10 M, similar to the high-affinity monoclonal antibodies described in the SARS-CoV-2 study. SPAC977.17 antibody specificity can be assessed through cross-reactivity testing against a panel of related S. pombe proteins, particularly those with sequence homology in the epitope region. Unlike antibodies against highly conserved proteins, those targeting species-specific regions (as seen with the SARS-CoV-2 antibodies that don't cross-react with SARS-CoV) offer superior specificity for research applications. Sensitivity comparisons should include detection limit determinations under standardized conditions, typically reported as the minimum detectable protein concentration in nanograms. While polyclonal antibodies often provide higher sensitivity through recognition of multiple epitopes, monoclonal antibodies like those available for many S. pombe proteins offer greater batch-to-batch consistency. Researchers should also consider epitope accessibility across different applications—antibodies recognizing linear epitopes typically perform better in Western blots, while those recognizing conformational epitopes excel in applications using native proteins. Finally, validation breadth across multiple techniques (Western blot, immunofluorescence, immunoprecipitation) indicates versatility and robust performance across experimental contexts .

What innovative research applications can benefit from SPAC977.17 antibody beyond standard techniques?

Beyond conventional applications, SPAC977.17 antibody enables several innovative research approaches that expand our understanding of S. pombe biology. Proximity-dependent labeling techniques, such as BioID or APEX, can be enhanced by conjugating SPAC977.17 antibody to these enzymes, allowing identification of spatial protein interaction networks in living cells. High-resolution imaging techniques including super-resolution microscopy (STORM, PALM, or SIM) benefit from highly specific antibodies to visualize subcellular distributions and dynamic interactions at nanometer resolution, far beyond the diffraction limit of conventional microscopy. For studying protein dynamics, combining SPAC977.17 antibody with live-cell imaging techniques such as Fluorescence Recovery After Photobleaching (FRAP) can reveal protein turnover rates and mobility within different cellular compartments. In microfluidic systems designed for single-cell analysis, the antibody can be utilized for on-chip immunocapture and detection, enabling correlation of protein expression with other cellular parameters across thousands of individual cells. Mass cytometry (CyTOF) applications benefit from metal-conjugated antibodies for high-dimensional protein profiling at the single-cell level, particularly useful when studying heterogeneous yeast populations under stress conditions. For structural biology, antibody-assisted cryo-electron microscopy may stabilize protein complexes involving SPAC977.17, facilitating structural determination. Additionally, biosensor development using SPAC977.17 antibody fragments (Fab or scFv) conjugated to fluorophores or quantum dots enables real-time monitoring of protein dynamics in living systems .

How should researchers analyze and interpret conflicting results between antibody-based techniques?

When faced with conflicting results between different antibody-based techniques, researchers should implement a systematic approach to reconcile discrepancies and determine the most reliable findings. Begin by evaluating the inherent differences between techniques—Western blot detects denatured proteins while immunofluorescence observes proteins in a more native state, potentially explaining differential detection if the epitope accessibility varies between conditions. Antibody validation status for each technique should be rigorously reviewed, as an antibody may be validated for Western blot but not for immunoprecipitation or immunofluorescence. Consider potential technical issues specific to each method, such as fixation artifacts in immunofluorescence or transfer efficiency problems in Western blots. Cross-validate findings using orthogonal methods that don't rely on antibodies, such as mass spectrometry for protein identification or RNA-seq for expression levels. Biological explanations for discrepancies should be explored, including potential post-translational modifications, protein isoforms, or protein-protein interactions that may mask epitopes in specific cellular contexts. When techniques disagree on protein abundance, consider the quantitative limitations of each method—Western blots may provide better quantification than immunofluorescence for total protein levels, while the latter offers superior spatial information. Document all experimental conditions in detail, as seemingly minor variations in protocols can significantly impact results. Prepare a systematic comparison table listing all variables and outcomes across techniques to visualize patterns in the discrepancies, which may reveal the underlying causes of conflicting results .

What statistical approaches are most appropriate for analyzing quantitative data from SPAC977.17 antibody experiments?

Selecting appropriate statistical methods for quantitative analysis of SPAC977.17 antibody data requires consideration of experimental design, data distribution, and specific research questions. For comparing protein expression levels between two experimental groups (such as treated versus untreated cells), begin with descriptive statistics to characterize central tendency and dispersion, typically reporting means with standard deviations or medians with interquartile ranges depending on data normality. Test for normal distribution using Shapiro-Wilk or Kolmogorov-Smirnov tests before selecting parametric (t-test) or non-parametric (Mann-Whitney U) methods for two-group comparisons. For multi-group comparisons common in S. pombe studies examining various growth conditions or genetic backgrounds, ANOVA with appropriate post-hoc tests (Tukey's HSD or Dunnett's for comparing to control) should be applied after confirming normality and homogeneity of variance. When analyzing time-course experiments tracking SPAC977.17 expression over cell cycle progression, repeated measures ANOVA or mixed-effects models are most appropriate, accounting for within-subject correlations. For correlational studies examining relationships between SPAC977.17 levels and other cellular parameters, calculate Pearson's r for normally distributed data or Spearman's rho for non-parametric associations. Statistical power analysis should be performed a priori to determine appropriate sample sizes, typically aiming for power ≥0.8 with α=0.05. For complex experimental designs incorporating multiple variables, regression analysis or factorial ANOVA may be required. All statistical analyses should include multiple biological replicates (minimum n=3) and report effect sizes alongside p-values to indicate biological significance beyond statistical significance .

How can computational antibody design approaches improve future generations of SPAC977.17 antibodies?

Computational antibody design approaches, such as RosettaAntibodyDesign (RAbD), offer transformative potential for developing enhanced SPAC977.17 antibodies with superior performance characteristics. These computational frameworks sample diverse sequence, structure, and binding spaces to optimize antibody-antigen interactions at the molecular level. Future SPAC977.17 antibodies could benefit from structural bioinformatics analyses that identify optimal binding epitopes based on accessibility, conservation, and structural stability. By leveraging canonical clusters of Complementarity-Determining Regions (CDRs), computational methods can graft structural elements from existing high-performance antibodies to create novel constructs with improved binding properties. Sequence design according to amino acid profiles of successful antibody clusters enables rational optimization of binding interfaces, potentially enhancing both affinity and specificity. Flexible-backbone design protocols incorporating cluster-based CDR constraints allow exploration of conformational space not accessible through traditional experimental approaches alone. Evaluation metrics such as design risk ratio and antigen risk ratio provide statistical frameworks for assessing computational designs before experimental validation, streamlining resource allocation for antibody development. As demonstrated in the RAbD benchmark study, computational approaches have successfully improved antibody affinities 10 to 50-fold by replacing individual CDRs with new clusters and lengths. Applied to SPAC977.17, these techniques could yield antibodies with enhanced specificity for distinguishing between closely related yeast proteins, higher sensitivity for detecting low-abundance targets, and improved performance across multiple experimental modalities .

What emerging technological platforms could revolutionize applications of SPAC977.17 antibody in research?

Several emerging technological platforms are poised to revolutionize applications of SPAC977.17 antibody in yeast biology research. Single-cell proteomics approaches using mass spectrometry or multiplexed ion beam imaging (MIBI) enable quantification of SPAC977.17 alongside hundreds of other proteins at single-cell resolution, revealing heterogeneity within yeast populations that bulk approaches cannot detect. Spatial transcriptomics combined with antibody-based protein detection allows correlation between SPAC977.17 protein levels and local gene expression patterns, providing insights into regulatory mechanisms. Microfluidic antibody capture technologies enable ultra-sensitive detection of low-abundance proteins from minimal sample volumes, potentially detecting SPAC977.17 from single cells or specific cellular compartments. Nanobody and aptamer development represents an alternative to traditional antibodies, offering smaller binding molecules with superior tissue penetration and potentially reduced cross-reactivity in complex samples. CRISPR-based tagging systems paired with antibody detection provide opportunities for studying endogenous protein dynamics without overexpression artifacts. Digital pathology platforms utilizing machine learning algorithms can analyze antibody staining patterns across thousands of samples to identify subtle phenotypic changes associated with SPAC977.17 dysfunction. Organ-on-a-chip technologies combined with antibody-based detection systems enable studies of protein function in microenvironments that better recapitulate in vivo conditions. These emerging platforms collectively enhance the precision, sensitivity, and contextual information obtainable from SPAC977.17 antibody applications, enabling more sophisticated investigations into protein function, regulation, and interaction networks in fundamental yeast biology research .